Nucryst shakes up management, sidelines program

Nucryst Pharmaceuticals has shaken up its management and shelved one of its development programs. Nucryst announced that it had "discontinued the development of, and out-licensing initiatives for, the current formulation of NPI 32101 silver to treat inflammatory bowel disease."

David C. McDowell, vice president operations, adds R&D responsibilities to his job description and Edward Gaj has been named vice president marketing. Katherine J. Turner, PhD, vice president research and development, is leaving to explore outside opportunities.

- read Nucryst's release

Suggested Articles

Vital strategies for steriles development to ensure more flexibility within drug development.

After Mallinckrodt's terlipressin beat placebo at reversing kidney failure, an FDA panel will discuss the phase 3 trial's surrogate endpoint.

Operation Warp Speed is living up to its name as AstraZeneca is teaming up with IQVIA to boost its R&D for its pandemic shot.